

PainChek receives European patent for pain assessment technology

PainChek® Ltd (ASX: PCK) ("PainChek" or "the Company"), developer of the world's first smartphone-based pain assessment and monitoring application, is pleased to announce it has been granted a patent in 20 European nations by the European Patent Office (EPO).

The patent application, entitled "A Pain Assessment Method and System", enables PainChek to safeguard the intellectual property of its pain assessment and monitoring technology within the European market. This includes Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Slovenia, Spain, Sweden, Switzerland and the United Kingdom.

The patent protection for all these regions is until 2035.

This patent (patent no. 3182893) further strengthens PainChek's global intellectual property portfolio, which includes existing patents in the USA, Japan, and China.

Philip Daffas, CEO of PainChek, commented:

"The granting of this European patent is a pivotal achievement for PainChek as it solidifies our position in one of the world's largest healthcare markets, including the UK which is a particularly important growth region for the company. This protection enhances our ability to deliver innovative pain assessment solutions to a broader audience, ensuring better pain assessment and management for individuals in need."

This release has been authorised for release by PainChek CEO Philip Daffas.

For more information:

Natalie Climo

Company Secretary, PainChek

natalie.climo@boardroomlimited.com.au

02 8016 2875

Philip Daffas

CEO, PainChek

philip.daffas@painchek.com

0406 537 235

About PainChek®

[PainChek®](#) is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek's AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek's detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom, with FDA review in the United States currently in progress.

PainChek® has contracts with over 1,000 aged care facilities, with more than 5,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>